Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kyowa Kirin Co., Ltd.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Voluntary written informed consent for study participation must be obtained
A histologically or cytologically confirmed advanced/recurrent non-small-cell lung cancer
History of ≥1 prior chemotherapy regimen (treatment with EGFR tyrosine kinase inhibitors will be counted as one regimen)
ECOG PS of 0 or 1
Life expectancy of ≥3 months
Poor metabolizers as defined by CYP2C19 genotype
You may not be if
Anti-cancer chemotherapy, anti-cancer therapy with EGFR-TKI, hormone therapy, radiotherapy, immunotherapy, other investigational agents or anti-cancer antibody therapy within 28 days prior to ARQ 197 dose
Surgery for cancer within 28 days prior to ARQ 197 dose
Active double cancer
Known symptomatic brain metastases
An intercurrent illness that is uncontrolled (e.g., infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic arrhythmia, interstitial pneumonia)
Pregnant or lactating
Subjects who wish to have a child and who would not agree to use contraceptive measures
Clareo Health | A Study of ARQ 197 in Combination With Erlotinib
